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Objectives: To describe medication use patterns and adherence rates for 
schizophrenia patients after initiating antipsychotic treatment in Tianjin, 
China. MethOds: Data were extracted from the Tianjin Urban Employee Basic 
Medical Insurance database (2008-2010). Adult patients with a schizophrenia 
diagnosis, newly initiating or restarting antipsychotics (no antipsychotics during 
previous 90 days) with 12-month continuous enrollment after their first observed 
antipsychotic prescription were included. Patients’ medication prescribing patterns 
and antipsychotic adherence are described. Results: A total of 1216 patients were 
identified, with a mean (SD) age of 51.43 (12.48) years, 54.11% female. 83.14% of 
patients initiated with one antipsychotic and 16.86% with ≥ 2 antipsychotics. 37.99% 
of patients were initiated on typical antipsychotics, 52.06% on atypicals, and 9.95% 
on both. A higher portion of typical initiators were co-prescribed antianxiety and 
anticholinergic medications than atypical starters (both p< 0.001). During the follow-
ing 12 months, the majority of patients remained on medications from their initial 
antipsychotic class (80.74% of typical initiators vs. 86.41% of atypical initiators) or 
the same medication (66.45% of typical initiators vs. 70.93% of atypical initiators). 
More typical initiators switched to, or augmented with, atypical antipsychotics than 
atypical initiators to/with typical antipsychotics (19.26% vs. 13.59%, P= 0.011). During 
the following 3, 6 and 12 months, antipsychotic continuation rates (≤ 30 days gap) 
were 50.33%, 23.60%, and 8.88%, respectively. Medication Possession Ratios were low, 
with means (SD) of 0.58 (0.32), 0.44 (0.30), and 0.34 (0.27) for the 3, 6 and 12 months, 
respectively. cOnclusiOns: More individuals with schizophrenia were treated 
with atypicals rather than typical antipsychotics. The majority of patients tended 
to stay with one antipsychotic drug class or the same medication. Patients’ adher-
ence to prescribed antipsychotics was low. This study highlights the importance 
of selecting an effective medication when starting antipsychotic therapy in China. 
However much could be done to improve treatment adherence.
MUscUlar-skeletal disorders – clinical outcomes studies
PMs1
tHe iMPact of coMorbidities on Utility cHanges in lower-liMb 
osteoartHritis : kHoala stUdy
Hosseini K.1, Gaujoux-Viala C.2, Baertschi A.3, Oudot J.3, Rat A.C.1, Guillemin F.1
1CHU Nancy, Clinical Epidemiology and Evaluation; Université de Lorraine, Paris Descartes 
University, APEMAC, EA 4360, Nancy, France, 2• Montpellier I University, Nîmes University 
Hospital, Rheumatology, France • EA 2415, Montpellier I University, Nîmes University Hospital, 
Rheumatology Department, France, Paris, France, 3CHU Nancy, Clinical Epidemiology and 
Evaluation, Nancy, France
Objectives: 1) To determine the minimal important change (MID) of indirect util-
ity score for patients with osteoarthritis (OA) over 3-year follow up, and 2)Estimate 
the impact of comorbidity for patients reaching the MID. MethOds: A total of 878 
patients with symptomatic knee or/and hip OA of KHOALA cohort were included. 
Comorbidity were assessed by Functional Comorbidity Index (FCI). Utility score 
was assessed using SF-6D, and limitation in activities by WOMAC function score 
(0-100,0 is better), at baseline and 3-year. The MID of utility was assessed using 
standard error of measurement (SEM). According to MID, patients were classified as 
negative/positive change or unchanged. Two separate multinomial logistic models 
were fitted to determine predictors of positive or negative change over the MID 
threshold. Both models included sociodemographic characteristics and the mean 
difference of WOMAC score between baseline and 3-year. Results: A total of 650 
OA patients completed the questionnaire at both times. The mean (SD) utility was 
0.664 (±0.110) at baseline and 0.667 (±0.110) at 3-year. Patients have on average 2.5 
(±1.94) comorbidities and a signifcant (p< .0001) decrease of the WOMAC function 
score at 3-year. The MID of SF-6D utility score was 0.067: 147 patients classified with 
negative and 156 with a positive change. In the first model including the number 
of comorbidities, patients with a decrease of the WOMAC function score had an 
increased utility (OR= 0.95; p< .0001). In the second model, patients with pneumo-
logic (OR= 1.88; p= 0.03) or neurologic (OR= 2.73;p= 0.047) disease were likely to have 
improved utility, while patients having a psychiatric disease were less likely to have 
an improvement (OR= 0.54;p= 0.029). cOnclusiOns: According to MID, about half 
of patients had a positive or negative change in their utility score. Compared to 
functional severity of OA, comorbidities have a relatively marginal impact on indi-
rect utility score. This suggests that clinically, considering the functional severity 
of OA remains a first priority.
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Objectives: Rheumatoid arthritis (RA) is a chronic, systemic disease associated 
with comorbidities and extra-articular manifestations (EAM) . The main objective 
of the study was to estimate the frequency and impact of comorbidities and EAM in 
well-defined RA patients. MethOds: A prospective study was conducted at a ter-
tiary care hospital between the years 2009 & 2012. Patients (age ≥ 18 years) with RA, 
fulfilling the revised criteria of the American college of rheumatology (1987 & 2010), 
were enrolled in the study. Standard clinical, laboratory and radiological measures 
of RA and details of comorbidities and EAM were recorded using patient hospital 
records. Results: Of 602 RA patients, 481 (79.9%) females and 121 (20.1%) males 
were present. Mean age of 47.57±12.78 years, mean disease duration of 4.52±4.75 
was conducted. Family impact was assessed as: Financial burden, Employment 
Burden, and Time-related burden. Binary and multinomial logistic regressions 
were conducted to compare likelihood of adverse family impact across ASD, DD 
without ASD, MHC without ASD, and DD and MHC without ASD, after adjust-
ing for socio-demographics, number of special children in the household, child’s 
functional ability, and presence of a physical condition. Results: Majority of 
the sample were older children (6-17 years), Whites, caregivers with ≥ 200% FPL 
income and greater than high school education. Sixteen percent (n= 2,801) of the 
caregivers had a child with an ASD diagnosis. Caregivers of children with ASD 
were more likely to have financial burden than caregivers of children with DD 
(AOR= 1.45, 95% CI= 1.10-1.91) and MHC (AOR= 1.59, 95% CI= 1.33-1.91). There were 
no significant differences in financial burden reports between caregivers of chil-
dren with ASD and those with both DD and MHC. Caregivers of children with ASD 
were also more likely to leave a job (employment), as compared to caregivers of 
children with DD (AOR= 1.57, 95% CI= 1.23-2.00), MHC (AOR= 3.06, 95% CI= 2.51-3.74), 
or both (AOR= 1.73, 95% CI= 1.36-2.20). Caregivers of children with ASD were more 
likely to report time-related burden as compared to caregivers of children with 
MHC (AOR= 2.87, 95% CI= 2.18-3.78) and DD and MHC (AOR= 1.80, 95% CI= 1.32-
2.44). cOnclusiOns: Caregivers of children with ASD are more likely to report 
an adverse family impact as compared to caregivers of children with DD, MHC, 
or both.
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Objectives: With increasing prevalence of dementia worldwide the interest in the 
dementia burden and impact on the health care system is rising. Yet comprehensive 
information about long-term needs and patterns of care of dementia patients and 
informal caregivers is scarce. Dementia specific registries provide an opportunity 
to investigate these aspects by long-term-data analysis. However, so far no inter-
national standards exist for developing a dementia registry. MethOds: An inter-
disciplinary team (psychiatry, public health, psychology, medical sociology, health 
economics and gerontology) established a registry structure in 2012. In the concep-
tion phase, existing registries, studies of dementia and best practice scenarios were 
identified. Features were combined in our concept and inclusion criteria, time for 
follow-up, fields of particular relevance and instruments were determined. A ques-
tionnaire was built and tested in exemplar sites. Results: The pilot study started 
with prospective interviews in January 2013 to evaluate the concept. The inclusion 
criterion is a dementia diagnosis according to ICD-10. Patients are recruited from 
the regional memory clinic during the process of diagnosis. Patient drop outs occur 
after initial inclusion because of other ensured diagnosis such as depression. Both 
patients and caregivers are interviewed separately with internationally approved 
valid instruments. The follow-up will take place after 6, 12 months and annually 
until death or loss to follow-up. cOnclusiOns: Existing dementia registries are 
very rare and heterogeneous in their structure, with currently no standards on 
quality indicators and processes. However, the complexity of dementia requires a 
sophisticated organizational structure for covering all aspects of dementia. Despite 
the challenges, our dementia registry structure provides essential, comprehensive 
and long-term information about the dementia care setting. The research is funded 
by the European Commission, ICT FP7, project ID 287509.
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Objectives: There is an increasing demand for medication reviews to improve 
the quality of prescribing for patients with chronic illness such as psychiatric 
patients. Traditionally, this has been undertaken by physicians. Pharmacists have 
also proven to be a resource in this field but registered nurses are the health profes-
sionals spending most time directly with the patient and very few studies inves-
tigate nurses’ role and potential in improving the appropriateness of medication. 
Therefore, the objective of this study is to investigate the effect of educating nurses 
in general pharmacology and conducting systematic medication reviews using 
computer based screening. The effect is evaluated in a controlled interventional 
study. MethOds: An interventional study including 2 acute psychiatric wards. In 
one ward nurses’ will receive pharmacological training and the other ward will func-
tion as a control. The nurses will perform approximately 250 medication reviews 
followed by medication reviews performed by pharmacologists. Primary outcomes 
are the respective frequencies, types and severity of potential inappropriate pre-
scriptions identified by the nurses and pharmacologists and an estimation of the 
interratervariability between the two professions. Results: The hypothesis is that 
nurse-led medication reviews will reduce potential inappropriate prescribing and 
that training will increase nurses’ ability to identify and report potential inappropri-
ate prescribing. It is assumed that this intervention, in addition to a more appropri-
ate prescribing, will lead to a reduction in length of hospitalization for psychiatric 
patients. cOnclusiOns: The perspective for this study is to add knowledge about 
frequency, types and potential severity of potential inappropriate prescribing for 
psychiatric patients. The study will contribute with information regarding the effect 
of pharmacological training of nurses and possibly improve medication safety for 
psychiatric patients. Results from this study could serve as evidence, when hospital 
management makes decisions on how to accede the need for medication reviews 
as part of an ongoing accreditation process.
